


COULD THE
HEMATOLOGIC
CANCER
YOU JUST
DIAGNOSED...



ACTUALLY BE
BPDCN?

What the cd123 diagnostic
marker can tell you*

B | Blastic
P | Plasmacytoid
D | Dendritic
C | Cell
N | Neoplasm

Knowing can
be as simple
as cd123.

- Frequent reclassification and renaming has contributed to the underrecognition of BPDCN¹
- Sites of involvement include¹⁻³
 - Primary: bone marrow, peripheral blood, skin
 - Secondary: lymph nodes, viscera
- Early and accurate diagnosis is critical to proper management of patients with BPDCN¹
- BPDCN exhibits variable dermatologic and hematologic presentation³⁻⁷
 - 85% to 90% of patients with BPDCN present with skin lesions
 - 30% to 60% of patients present with leukemic disease

BPDCN MAY BE MISTAKEN FOR^{1,2,5,8}

AML	Leukemia cutis	Cutaneous lymphoma	
NHL	ALL	MDS	CMML

AML = acute myeloid leukemia; NHL = non-Hodgkin's lymphoma; ALL = acute lymphoblastic leukemia; MDS = myelodysplastic syndrome; CMML = chronic myelomonocytic leukemia.



*BPDCN diagnosis can include other markers, such as cd4, cd56, TCL1, and cd303 (BDCA2).¹

Visit BPDCNinfo.com for more information.

Stemline[®]

YOUR AML PATIENT... MAY NOT HAVE AML.

The signature marker triad **cd123, cd4, cd56**
allows for proper diagnosis of **BPDCN**



◀ **cd123** is rapidly emerging as a therapeutic target in hematologic cancer.¹

Consider adding **cd123** to initial hematologic panels^{1,2}

cd123, as part of the signature marker triad in combination with cd4 and cd56, is a key marker in identifying BPDCN—a particularly aggressive hematologic cancer that often presents with skin lesions.

Key features of **cd123** expression^{5,9-11}

- Highly expressed on BPDCN cells (~95%) and negligibly expressed on healthy cells
- Can be identified through any biopsy of malignant cells
- Can be both a diagnostic marker and a therapeutic target in BPDCN

cd123 SHOULD BE ADDED TO INITIAL HEMATOLOGIC DIAGNOSTIC PANELS.¹

Visit BPDCNinfo.com for more information.

References: **1.** Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. *Br J Haematol.* 2016;174(2):188-202. **2.** Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. *Cancer Control.* 2014;21(4):279-289. **3.** Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? *Surg Pathol Clin.* 2013;6(4):743-765. **4.** Sullivan JM, Rizzier DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. *Am Soc Hematol.* 2016;2016(1):16-23. **5.** Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. *Biol Blood Marrow Transplant.* 2016;22(8):1357-1367. **6.** Julia F, Petrel T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. *Br J Dermatol.* 2013;169(3):579-586. **7.** Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. *Cancer.* 2005;104(5):1022-1031. **8.** León-Martínez G, Meillón-García L, Morales-Polanco M, Soler-Montecinos L, Ortiz-Hidalgo C. Unusual morphologic presentations of blastic plasmacytoid dendritic cell neoplasm: report of two cases misdiagnosed as melanoma and leprosy. *Int J Surg Pathol.* 2014;22(1):76-82. **9.** Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. *Mod Pathol.* 2016;29(2):98-111. **10.** Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. *Blood.* 2014;124(3):385-392. **11.** Pemmaraju N. Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. *Curr Hematol Malig Rep.* 2017;12(6):510-512.